title: HPV16 oncoproteins promote cervical cancer invasiveness by upregulating specific matrix metalloproteinases.
abstract: Production of matrix metalloproteinases (MMPs) for degradation of extracellular matrix is a vital step in cancer metastasis. We investigated the effects of HPV16 oncoproteins (16E6, 16E6*I and 16E7), either individually or combined, on the transcription of 7 MMPs implicated in cervical cancer invasiveness. The levels of 7 MMPs reported to be increased in cervical cancer were determined in C33A stably expressing different HPV16 oncoproteins using quantitative RT-PCR and compared with invasion ability of cell lines using in vitro invasion and wound healing assays. Overexpression of MMP-2 and MT1-MMP was detected in HPV16E6E7 expressing cells which correlated with increased cell invasion. Combination of HPV oncoproteins always showed greater effects than its individual form. Inhibition of cell invasion using a specific MMP-2 inhibitor, OA-Hy, and anti-MT1-MMP antibody confirmed that invasion in these cells was dependent on both MMP-2 and MT1-MMP expression. Depletion of HPV16E6E7 by shRNA-mediated knock-down experiments resulted in decreased MMP-2 and MT1-MMP expression levels as well as reduced invasion ability which strongly suggested specific effects of HPV oncoproteins on both MMPs and on cell invasion. Immunohistochemistry study in invasive cervical cancers confirmed the enhanced in vivo expression of these two MMPs in HPV16-infected cells. In addition, possible sites required by HPV16E6E7 on the MMP-2 and MT1-MMP promoters were investigated and PEA3 (at -552/-540 for MMP-2, -303 for MT1-MMP) and Sp1 (at -91 for MMP-2, -102 for MT1-MMP) binding sites were shown to be essential for mediating their transactivation activity. In conclusion, our study demonstrated that HPV16E6 and E7 oncoproteins cooperate in promoting cervical cancer invasiveness by specifically upregulating MMP-2 and MT1-MMP transcription in a similar manner.
authors: Molecular Medicine Graduate Program, Faculty of Science, Mahidol University, Bangkok, Thailand.
authors: Jittranan
authors: J
authors: Kaewprag
authors: Wareerat
authors: W
authors: Umnajvijit
authors: Jarunya
authors: J
authors: Ngamkham
authors: Mathurose
authors: M
authors: Ponglikitmongkol
mesh_terms: D002460:Cell Line; D004789:Enzyme Activation; D005260:Female; D018093:Gelatinases / Q000378:metabolism; D005786:Gene Expression Regulation; D055785:Gene Knockdown Techniques; D052162:Human papillomavirus 16 / Q000235:genetics / Q000378:metabolism*; D006801:Humans; D020778:Matrix Metalloproteinase 2 / Q000235:genetics / Q000378:metabolism; D061965:Matrix Metalloproteinase Inhibitors / Q000494:pharmacology; D020782:Matrix Metalloproteinases / Q000235:genetics / Q000378:metabolism*; D009361:Neoplasm Invasiveness; D015513:Oncogene Proteins / Q000235:genetics / Q000378:metabolism*; D009856:Oncogene Proteins, Viral / Q000235:genetics / Q000378:metabolism; D050725:Papillomavirus E7 Proteins / Q000235:genetics / Q000378:metabolism; D011401:Promoter Regions, Genetic; D011485:Protein Binding; D012097:Repressor Proteins / Q000235:genetics / Q000378:metabolism; D015533:Transcriptional Activation; D002583:Uterine Cervical Neoplasms / Q000235:genetics / Q000378:metabolism* / Q000473:pathology* / Q000821:virology; D014764:Viral Proteins / Q000235:genetics / Q000378:metabolism*
chemical_list: C068651:E6 protein, Human papillomavirus type 16; D061965:Matrix Metalloproteinase Inhibitors; D015513:Oncogene Proteins; D009856:Oncogene Proteins, Viral; D050725:Papillomavirus E7 Proteins; D012097:Repressor Proteins; D014764:Viral Proteins; C059731:oncogene protein E7, Human papillomavirus type 16; D018093:Gelatinases; D020782:Matrix Metalloproteinases; D020778:Matrix Metalloproteinase 2
references: Int J Biochem Cell Biol. 2008;40(6-7):1362-78
references: 18258475
references: J Virol. 2009 Oct;83(19):9863-74
references: 19640984
references: Cancer Res. 2005 Aug 1;65(15):6543-50
references: 16061633
references: Int J Cancer. 1996 Jan 17;65(2):209-13
references: 8567119
references: Cancer Res. 1996 Oct 15;56(20):4620-4
references: 8840974
references: J Clin Pathol. 1998 Feb;51(2):143-8
references: 9602689
references: J Virol. 1989 Oct;63(10):4417-21
references: 2476573
references: APMIS. 2010 Jun;118(6-7):471-93
references: 20553529
references: Biochem Biophys Res Commun. 2007 Apr 6;355(2):438-43
references: 17306229
references: Gene. 2000 Jan 25;242(1-2):75-86
references: 10721699
references: Cancer Res. 2001 Dec 15;61(24):8896-902
references: 11751414
references: J Gen Virol. 2005 May;86(Pt 5):1291-1296
references: 15831939
references: J Natl Cancer Inst. 2009 Mar 18;101(6):412-23
references: 19276448
references: Cancer Res. 2003 Oct 1;63(19):6537-42
references: 14559848
references: J Biol Chem. 1999 Oct 8;274(41):29130-7
references: 10506168
references: Nature. 1994 Jul 7;370(6484):61-5
references: 8015608
references: J Environ Pathol Toxicol Oncol. 2003;22(2):93-100
references: 14533872
references: BMC Cancer. 2005 Jun 30;5:68
references: 15989693
references: Biochem Cell Biol. 2006 Oct;84(5):713-9
references: 17167534
references: Biochem J. 2004 Aug 15;382(Pt 1):363-73
references: 15130087
references: Biochem Biophys Res Commun. 1999 Jan 27;254(3):542-7
references: 9920775
references: PLoS One. 2012;7(3):e33585
references: 22438955
references: Biochim Biophys Acta. 1996 Oct 9;1288(2):F55-78
references: 8876633
references: Biochem Res Int. 2012;2012:685267
references: 22496978
references: J Clin Invest. 2002 Dec;110(12):1831-8
references: 12488433
references: J Biol Chem. 2004 Mar 26;279(13):12734-43
references: 14718544
references: Oncogene. 2000 Sep 21;19(40):4611-20
references: 11030150
references: Mol Cancer Res. 2007 May;5(5):413-21
references: 17475671
references: J Gen Virol. 2012 May;93(Pt 5):1081-1092
references: 22278827
references: Cell. 1990 Dec 21;63(6):1129-36
references: 2175676
references: J Cell Sci. 2010 Dec 1;123(Pt 23):4182-93
references: 21062896
references: Virology. 1997 Feb 17;228(2):190-9
references: 9123825
references: J Cancer Res Clin Oncol. 2003 Feb;129(2):123-31
references: 12669237
references: Int J Gynecol Cancer. 2009 Aug;19(6):998-1003
references: 19820359
references: Oncol Rep. 2002 May-Jun;9(3):565-9
references: 11956628
references: Anticancer Res. 2005 Sep-Oct;25(5):3387-91
references: 16101153
references: Nat Rev Cancer. 2002 Mar;2(3):161-74
references: 11990853
references: Anticancer Res. 2006 Mar-Apr;26(2B):1543-56
references: 16619570
references: J Infect Dis. 2003 Apr 15;187(8):1246-56
references: 12696004
references: J Virol. 2005 Nov;79(22):14309-17
references: 16254365
references: J Virol. 2001 Jun;75(12):5559-66
references: 11356963
references: J Surg Res. 2008 May 1;146(1):32-42
references: 17543340
references: Clin Exp Metastasis. 2011 Dec;28(8):827-39
references: 21833756
references: Mol Cell Biol. 2008 Oct;28(19):5937-50
references: 18644862
references: Oncogene. 2001 Nov 26;20(54):7888-98
references: 11753671